IN2014CN02906A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02906A
IN2014CN02906A IN2906CHN2014A IN2014CN02906A IN 2014CN02906 A IN2014CN02906 A IN 2014CN02906A IN 2906CHN2014 A IN2906CHN2014 A IN 2906CHN2014A IN 2014CN02906 A IN2014CN02906 A IN 2014CN02906A
Authority
IN
India
Prior art keywords
domain
antigen binding
intracellular
mammal
disclosed
Prior art date
Application number
Other languages
English (en)
Inventor
Rimas J Orentas
Crystal L Mackall
Ira H Pastan
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of IN2014CN02906A publication Critical patent/IN2014CN02906A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN2906CHN2014 2011-10-20 2012-10-19 IN2014CN02906A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549516P 2011-10-20 2011-10-20
PCT/US2012/061025 WO2013059593A1 (en) 2011-10-20 2012-10-19 Anti-cd22 chimeric antigen receptors

Publications (1)

Publication Number Publication Date
IN2014CN02906A true IN2014CN02906A (enrdf_load_stackoverflow) 2015-07-03

Family

ID=47143305

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2906CHN2014 IN2014CN02906A (enrdf_load_stackoverflow) 2011-10-20 2012-10-19

Country Status (11)

Country Link
US (1) US9868774B2 (enrdf_load_stackoverflow)
EP (1) EP2768863B1 (enrdf_load_stackoverflow)
JP (2) JP6267644B2 (enrdf_load_stackoverflow)
CN (2) CN103946242A (enrdf_load_stackoverflow)
AU (2) AU2012325915A1 (enrdf_load_stackoverflow)
BR (1) BR112014008849A2 (enrdf_load_stackoverflow)
CA (1) CA2851795C (enrdf_load_stackoverflow)
ES (1) ES2654060T3 (enrdf_load_stackoverflow)
IN (1) IN2014CN02906A (enrdf_load_stackoverflow)
RU (1) RU2644243C2 (enrdf_load_stackoverflow)
WO (1) WO2013059593A1 (enrdf_load_stackoverflow)

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2851795C (en) 2011-10-20 2018-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
PL2855667T3 (pl) 2012-05-25 2024-03-25 Cellectis Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii
WO2013187495A1 (ja) 2012-06-14 2013-12-19 中外製薬株式会社 改変されたFc領域を含む抗原結合分子
CA2889055C (en) 2012-10-24 2024-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
EP3653212B1 (en) 2012-12-20 2023-04-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
UY35340A (es) 2013-02-20 2014-09-30 Novartis Ag Marcaje efectivo de leucemia humana usando células diseñadas con un receptor quimérico de antígeno anti-cd123
LT2958943T (lt) 2013-02-20 2020-01-27 The Trustees Of The University Of Pennsylvania Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP6493692B2 (ja) 2013-03-15 2019-04-10 セルジーン コーポレイション 修飾されたｔリンパ球
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
KR102238226B1 (ko) 2013-05-14 2021-04-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
US9701758B2 (en) 2013-05-24 2017-07-11 Board Of Regents, The University Of Texas System Anti-CD19 scFv (FMC63) polypeptide
EP3038636B1 (en) 2013-08-30 2018-11-07 Board of Regents, The University of Texas System Administration of kynurenine depleting enzymes for tumor therapy
EP4269421A3 (en) 2013-10-11 2023-12-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Tem8 antibodies and their use
EP3066118B1 (en) 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CN103589742A (zh) * 2013-11-07 2014-02-19 申峰 嵌合体抗原受体胞内段的基因及其编码蛋白
PL3070168T3 (pl) * 2013-11-11 2024-10-28 Chugai Seiyaku Kabushiki Kaisha Cząsteczka wiążąca antygen zawierająca zmodyfikowany region zmienny przeciwciała
WO2015077789A2 (en) 2013-11-25 2015-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
RU2714902C2 (ru) 2013-12-19 2020-02-20 Новартис Аг Химерные рецепторы антигена против мезотелина человека и их применение
EP4420663A3 (en) * 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
US11028143B2 (en) 2014-01-21 2021-06-08 Novartis Ag Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
CA2938887C (en) 2014-02-14 2023-04-11 Laurence J. N. Cooper Chimeric antigen receptors and methods of making
CN103820393B (zh) * 2014-02-24 2016-09-07 西比曼生物科技（上海）有限公司 工程化cd20靶向性的nkt细胞及其制备方法和应用
IL280215B (en) 2014-04-07 2022-07-01 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
JP6765968B2 (ja) 2014-04-10 2020-10-07 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 薬物制御による導入遺伝子の発現
AU2015292811B2 (en) 2014-07-21 2019-12-19 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
CN112481283A (zh) 2014-07-21 2021-03-12 诺华股份有限公司 使用cd33嵌合抗原受体治疗癌症
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
KR102048855B1 (ko) * 2014-07-29 2019-11-26 셀렉티스 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체
CA2958553A1 (en) 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
CA2959508A1 (en) 2014-08-29 2016-03-03 Board Of Regents, The University Of Texas System Administration of kynurenine depleting enzymes for tumor therapy
ES2777305T3 (es) 2014-09-04 2020-08-04 Cellectis Receptores de antígeno quiméricos específicos de la glicoproteína trofoblástica (5T4, TPBG) para inmunoterapia contra el cáncer
EA201790624A1 (ru) 2014-09-17 2017-08-31 Новартис Аг Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии
US10604582B2 (en) 2014-09-17 2020-03-31 The United States Of America, As Represented By The Secretary, Department Of Health Anti-CD276 antibodies (B7H3)
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016061286A2 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
ES2806126T3 (es) 2014-11-05 2021-02-16 Univ Texas Receptores de antígenos quiméricos (CAR) dirigidos de forma selectiva a complejos proteicos
JP2017535284A (ja) * 2014-11-05 2017-11-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
TWI831044B (zh) 2014-11-11 2024-02-01 日商中外製藥股份有限公司 抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法
EP3766895B1 (en) 2014-12-03 2024-07-10 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
AU2015361261B2 (en) 2014-12-08 2020-03-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD70 chimeric antigen receptors
BR112017013690A2 (pt) 2014-12-24 2018-03-06 Ucl Business Plc célula
EP4036109A3 (en) 2014-12-29 2022-10-12 Novartis AG Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
JP6912386B2 (ja) 2015-01-26 2021-08-04 ザ ユニバーシティー オブ シカゴ 癌特異的なＩＬ１３Ｒα２を認識するＣＡＲ Ｔ細胞
WO2016123142A1 (en) 2015-01-26 2016-08-04 The University Of Chicago IL13RAα2 BINDING AGENTS AND USE THEREOF IN CANCER TREATMENT
US20180051089A1 (en) 2015-01-26 2018-02-22 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
JP6886404B2 (ja) 2015-01-30 2021-06-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 初代造血細胞におけるタンパク質送達
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CA2976236A1 (en) 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
WO2016149578A1 (en) 2015-03-19 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
PL3271389T3 (pl) 2015-03-20 2020-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizujące przeciwciała wiążące się z gp120 i ich stosowanie
IL303972A (en) 2015-04-08 2023-08-01 Novartis Ag CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
EP4234685A3 (en) 2015-04-17 2023-09-06 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
CN113502270B (zh) 2015-06-10 2024-06-18 南克维斯特公司 用于治疗癌症的修饰的nk-92细胞
CN108026151B (zh) 2015-06-19 2022-07-15 塞巴斯蒂安·科博尔德 Pd-1-cd28融合蛋白及其在医学中的用途
CA2986604A1 (en) 2015-06-26 2016-12-29 University Of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
JP7146632B2 (ja) 2015-07-21 2022-10-04 ノバルティス アーゲー 免疫細胞の有効性および増大を改善する方法
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
WO2017035251A1 (en) 2015-08-25 2017-03-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cells modified to overexpress c-myb
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
CN116334205A (zh) 2015-09-03 2023-06-27 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
WO2017044699A1 (en) * 2015-09-10 2017-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 chimeric antigen receptors
EP3359570A1 (en) 2015-10-07 2018-08-15 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
DK3362569T3 (da) 2015-10-16 2021-10-18 Univ Muenchen Ludwig Maximilians Cxcr6-transducerede t-celler til målrettet tumorterapi
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
EP3368075B1 (en) 2015-10-27 2020-01-29 Board of Regents, The University of Texas System Chimeric antigen receptor molecules and uses thereof
JP2018536436A (ja) 2015-12-04 2018-12-13 ノバルティス アーゲー 免疫腫瘍学のための組成物および方法
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
US11542486B2 (en) 2016-03-02 2023-01-03 Board Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
WO2017177149A2 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
CN105968210B (zh) * 2016-05-13 2019-05-31 深圳生创精准医疗科技有限公司 靶向cd22的强杀伤性嵌合抗原受体t细胞及其在制备治疗肿瘤的药物中的用途
CN106167527A (zh) * 2016-06-13 2016-11-30 长沙郝怡雅医药科技有限公司 一种融合蛋白
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
MX2018015414A (es) 2016-06-30 2019-08-01 Hoffmann La Roche Terapia de célula t adoptiva mejorada.
AU2017332161B9 (en) 2016-09-21 2024-08-22 The United States Government As Represented By The Department Of Veterans Affairs Chimeric antigen receptor (car) that targets chemokine receptor CCR4 and its use
WO2018057447A1 (en) 2016-09-23 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
KR20190049887A (ko) 2016-09-29 2019-05-09 난트케이웨스트, 인크. 감소된 면역원성을 갖는 hla 클래스 i-결핍 nk-92 세포
CA3039646A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
EP4190335A1 (en) 2016-10-13 2023-06-07 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
CN107964549B (zh) * 2016-10-20 2020-12-08 上海恒润达生生物科技有限公司 靶向cd22的嵌合抗原受体及其用途
JP7100028B2 (ja) 2016-10-20 2022-07-12 セルジーン コーポレイション セレブロン系のヘテロ二量体化可能なキメラ抗原受容体
WO2018111981A1 (en) 2016-12-13 2018-06-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
CA3048907C (en) 2017-01-06 2023-05-23 Nantkwest, Inc. Genetically modified nk-92 cells with decreased cd96/tigit expression
US10183993B2 (en) * 2017-01-09 2019-01-22 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
KR102585848B1 (ko) 2017-02-24 2023-10-11 마크로제닉스, 인크. Cd137 및 종양 항원에 결합할 수 있는 이중특이적 결합 분자, 및 그것의 용도
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
CN110831961B (zh) * 2017-03-03 2024-01-02 黑曜石疗法公司 用于免疫疗法的cd19组合物和方法
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP3601561A2 (en) 2017-03-22 2020-02-05 Novartis AG Compositions and methods for immunooncology
CN110461881B (zh) * 2017-03-27 2023-06-23 诺伊尓免疫生物科技株式会社 嵌合抗原受体
US11938153B2 (en) 2017-03-31 2024-03-26 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling
EP3592379B1 (en) 2017-03-31 2024-04-24 Cellectis SA Universal anti-cd22 chimeric antigen receptor engineered immune cells
CA3059643A1 (en) 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
EP3612210A4 (en) 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS
US11980640B2 (en) 2017-05-15 2024-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
CA3065126A1 (en) * 2017-06-01 2018-12-06 Innovative Cellular Therapeutics CO., LTD. Chimeric antigen receptor cell preparation and uses thereof
US12384830B2 (en) 2017-06-02 2025-08-12 Regents Of The University Of Minnesota Compositions and methods for improving immunotherapy
US11883431B2 (en) 2017-06-05 2024-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T-cells modified to overexpress PHF19
CN110769898A (zh) * 2017-06-22 2020-02-07 南加利福尼亚大学 使用嵌合抗原受体工程化自然杀伤细胞作为化学治疗药物运载体的联合癌症疗法
EP3645036A1 (en) 2017-06-30 2020-05-06 Cellectis Cellular immunotherapy for repetitive administration
US11235004B2 (en) 2017-06-30 2022-02-01 Innovative Cellular Therapeutics Holdings, Ltd. Lymphocyte cell lines and uses thereof
AU2018336791B2 (en) 2017-09-19 2025-08-21 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor T cell therapy and uses thereof
WO2019075055A1 (en) 2017-10-11 2019-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS
ES2958849T3 (es) 2017-10-16 2024-02-15 Lentigen Tech Inc Composiciones y métodos para tratar el cáncer con inmunoterapia anti-CD22
WO2019079569A1 (en) 2017-10-18 2019-04-25 Novartis Ag COMPOSITIONS AND METHODS FOR SELECTIVE DEGRADATION OF A PROTEIN
IL273961B2 (en) 2017-10-18 2025-04-01 Precigen Inc Polypeptide compositions containing spacers
WO2019084284A1 (en) 2017-10-27 2019-05-02 Coneksis, Inc. NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
JP7357616B2 (ja) 2017-12-05 2023-10-06 中外製薬株式会社 Ｃｄ３およびｃｄ１３７に結合する改変された抗体可変領域を含む抗原結合分子
WO2019117976A1 (en) 2017-12-17 2019-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide hydrogels and use thereof
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
DE112019000608B4 (de) 2018-01-31 2021-05-06 Nantkwest, Inc. Verwendung von 5 % humanalbumin in wasch- und erntemedien
AU2019218729A1 (en) 2018-02-06 2020-08-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
WO2019157130A1 (en) 2018-02-09 2019-08-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tethered interleukin-15 and interleukin-21
MX2020008390A (es) 2018-02-11 2020-12-07 Memorial Sloan Kettering Cancer Center Receptores de linfocitos t no restringidos a antígenos leucocitarios humanos (hla) y usos de los mismos.
AU2019225174A1 (en) 2018-02-23 2020-09-03 Endocyte, Inc. Sequencing method for CAR T cell therapy
US10780120B2 (en) * 2018-03-06 2020-09-22 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
CN112004829A (zh) 2018-03-12 2020-11-27 南克维斯特公司 Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途
MX2020010753A (es) * 2018-04-10 2021-01-29 Amgen Inc Receptores quimericos de dll3 y metodos para su uso.
BR112020020919A2 (pt) 2018-04-13 2021-04-06 Sangamo Therapeutics France Receptor de antígeno quimérico específico para receptor de interleucina-23
CA3096549A1 (en) 2018-04-16 2019-10-24 Board Of Regents, The University Of Texas System Human kynureninase enzymes and uses thereof
AU2019260656B2 (en) 2018-04-24 2025-08-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
KR102721140B1 (ko) 2018-05-22 2024-10-24 이뮤너티바이오, 인크. 폴록사머를 사용한 nk-92 세포 성장의 최적화
CN119432764A (zh) * 2018-05-22 2025-02-14 免疫生物公司 FC-ε CAR
US20210198628A1 (en) 2018-05-22 2021-07-01 Nantkwest, Inc. Basal media for growing nk-92 cells
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
CA3105601C (en) 2018-07-10 2024-01-16 Nantkwest, Inc. Generating cik nkt cells from cord blood
WO2020014245A1 (en) 2018-07-10 2020-01-16 Nantkwest, Inc. Cryopreservation
EP3820903A1 (en) 2018-07-12 2021-05-19 The United States of America, as represented by the Secretary, Department of Health and Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
WO2020028654A1 (en) 2018-08-01 2020-02-06 Nantkwest, Inc. Combined invasion and cytotoxicity assay using chemokine secreting target cells
KR20240046632A (ko) 2018-08-01 2024-04-09 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템
US20210324042A1 (en) 2018-08-01 2021-10-21 Nantkwest, Inc. Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
CN109022363A (zh) * 2018-08-15 2018-12-18 马晓冬 一种基于PiggyBac载体的CD-133-CAR-T系统构建方法
SG11202100935TA (en) 2018-09-28 2021-02-25 Massachusetts Inst Technology Collagen-localized immunomodulatory molecules and methods thereof
EP3872093A4 (en) 2018-10-22 2022-10-19 Shanghai Genbase Biotechnology Co., Ltd. ANTI-CLDN18.2 ANTIBODIES AND USES THEREOF
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
IL316887A (en) 2018-11-06 2025-01-01 Immunitybio Inc NK-92 cells with chimeric antigen receptor modification
US20220017594A1 (en) 2018-11-26 2022-01-20 Nantkwest, Inc. Il-2 dependent nk-92 cells with stable fc receptor expression
EP3670530A1 (en) 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
EP3935151A1 (en) 2019-03-08 2022-01-12 Klinikum der Universität München Ccr8 expressing lymphocytes for targeted tumor therapy
KR20220042353A (ko) 2019-06-24 2022-04-05 칠드런＇스 하스피틀 로스 앤젤레스 사람 흉선 세포 생성 및 t 세포 기능을 증진시키기 위한 bcl11b 과발현
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
US20220380474A1 (en) 2019-07-02 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Monoclonal antibodies that bind egfrviii and their use
CA3146987A1 (en) * 2019-07-17 2021-01-21 National University Of Singapore Functional binders synthesized and secreted by immune cells
CA3115917A1 (en) 2019-08-01 2021-02-04 Nantkwest, Inc. Anti-b7-h4 chimeric antigen receptor-modified nk-92 cells
US20220332780A1 (en) 2019-09-10 2022-10-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
EP4032907A4 (en) 2019-09-20 2023-07-05 Shanghai Genbase Biotechnology Co., Ltd. Bcma-targeted antibody and chimeric antigen receptor
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
CA3162892A1 (en) 2019-11-26 2021-06-03 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
PH12022551291A1 (en) 2019-11-26 2023-11-20 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2021183675A2 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Methods for generating engineered memory-like nk cells and compositions thereof
BR112022017924A2 (pt) 2020-03-10 2022-12-20 Massachusetts Inst Technology Composições e métodos para imunoterapia de câncer npm1c-positivo
BR112022019498A2 (pt) 2020-03-31 2022-11-16 Chugai Pharmaceutical Co Ltd Moléculas de ligação ao antígeno multiespecíficas de direcionamento de dll3 e uso das mesmas
EP4130040A4 (en) * 2020-04-02 2024-05-01 Nanjing Iaso Biotechnology Co., Ltd. FULLY HUMAN CHIMERIC ANTI-CD22 ANTIGEN RECEPTOR AND USE THEREOF
CN111484562B (zh) * 2020-04-25 2021-08-20 首都医科大学附属北京朝阳医院 一种靶向cd22蛋白的抗体、嵌合抗原受体和药物
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
IL298558A (en) 2020-05-27 2023-01-01 Antion Biosciences Sa Adapter molecules to re-direct car t cells to an antigen of interest
AU2021341969A1 (en) 2020-09-08 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
WO2022104035A2 (en) 2020-11-13 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
KR20230113767A (ko) 2020-11-24 2023-08-01 라이엘 이뮤노파마, 인크. 재생 t 세포의 제조 방법, 이를 포함하는 조성물 및 이의 사용 방법
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
KR20230154317A (ko) 2021-03-05 2023-11-07 상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. 항-cldn6 항체 및 이의 용도
US20240269182A1 (en) * 2021-05-27 2024-08-15 Innovative Cellular Therapeutics Holdings, Ltd. Modified Chimeric Antigen Receptor and Use thereof
WO2023021113A1 (en) 2021-08-18 2023-02-23 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
CA3241588A1 (en) 2021-12-31 2023-07-06 Sri Krishna T cell therapy with vaccination as a combination immunotherapy against cancer
TW202340474A (zh) 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途
CN118256444A (zh) * 2022-04-26 2024-06-28 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
CN119546338A (zh) 2022-06-10 2025-02-28 研究发展基金会 经改造FcRIIB选择性IgG1 Fc变体及其用途
CN118359729A (zh) * 2023-01-19 2024-07-19 武汉昭智生物技术有限公司 一种car分子、包含其的细胞或外泌体及它们的应用
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IN165717B (enrdf_load_stackoverflow) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
JP2002501488A (ja) 1997-03-20 2002-01-15 アメリカ合衆国 Ｃｄ２２を保有する細胞および腫瘍へ標的化された、組換え抗体および免疫複合体
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
AU2001297703B2 (en) * 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
EP1448584B1 (en) 2001-09-26 2010-05-19 The Government of the United States of America as represented by The Secretary of Health and Human Services Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
JP4813364B2 (ja) 2003-11-25 2011-11-09 アメリカ合衆国 突然変異型抗ｃｄ２２抗体および免疫複合体
KR20080031684A (ko) * 2005-06-14 2008-04-10 암젠 인코포레이티드 자가 - 완충성 단백질 제형
ES2564092T3 (es) 2005-07-29 2016-03-17 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Exotoxinas de pseudomonas mutadas con antigenicidad reducida
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
PT2197903E (pt) 2007-09-04 2015-01-02 Us Gov Health & Human Serv Delecções no domínio ii da exotoxina a de pseudomonas que reduzem toxicidade não específica
US8591889B2 (en) 2008-04-04 2013-11-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies specific for CD22
JP5795765B2 (ja) 2009-09-11 2015-10-14 アメリカ合衆国 低減した免疫原性を有する改良型シュードモナス（Ｐｓｅｕｄｏｍｏｎａｓ）外毒素Ａ
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2851795C (en) 2011-10-20 2018-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors

Also Published As

Publication number Publication date
CN103946242A (zh) 2014-07-23
US9868774B2 (en) 2018-01-16
JP6267644B2 (ja) 2018-01-24
RU2014118555A (ru) 2015-11-27
RU2644243C2 (ru) 2018-02-08
CN109485730A (zh) 2019-03-19
AU2017225049A1 (en) 2017-09-28
BR112014008849A2 (pt) 2017-09-12
CA2851795A1 (en) 2013-04-25
WO2013059593A1 (en) 2013-04-25
ES2654060T3 (es) 2018-02-12
AU2012325915A1 (en) 2014-04-24
CA2851795C (en) 2018-11-13
AU2017225049B2 (en) 2019-08-08
EP2768863B1 (en) 2017-09-27
EP2768863A1 (en) 2014-08-27
US20140274909A1 (en) 2014-09-18
JP2014534207A (ja) 2014-12-18
JP2017212996A (ja) 2017-12-07

Similar Documents

Publication Publication Date Title
IN2014CN02906A (enrdf_load_stackoverflow)
BR112015009003A2 (pt) receptores de antígeno quiméricos
CA2868121C (en) Anti-mesothelin chimeric antigen receptors
EP4424376A3 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
EP4413999A3 (en) Flt3-specific chimeric antigen receptors and methods using same
WO2014011993A3 (en) Epitope spreading associated with car t-cells
NZ612512A (en) Use of chimeric antigen receptor-modified t cells to treat cancer
WO2017147383A8 (en) Modified cells for immunotherapy
WO2013040142A3 (en) Bioinformatic processes for determination of peptide binding
IN2015DN00139A (enrdf_load_stackoverflow)
MX2020012742A (es) Metodo y composiciones para inmunoterapia celular.
SG10201808811QA (en) Method and compositions for cellular immunotherapy
JP2014534207A5 (enrdf_load_stackoverflow)
WO2014074532A3 (en) Compositions and methods for modulating cell signaling
MX2014010183A (es) Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
PH12014501970A1 (en) Antibodies to bradykinin b1 receptor ligands
WO2015077789A3 (en) Chimeric antigen receptors to control hiv infection
GB201108236D0 (en) Method
SG10201804439PA (en) Tagged chimeric effector molecules and receptors thereof
MX2015000439A (es) Metodos para evaluar la conveniencia de celulas t transducidas para administracion.
WO2013126733A8 (en) Use of icos-based cars to enhance antitumor activity and car persistence
UA99339C2 (ru) Антитело, которое специфично связывает человеческий tyrp1
TN2014000395A1 (en) Antibodies to bradykinin b1 receptor ligands
TN2013000246A1 (en) Use of chimeric antigen receptor-modified t cells to treat cancer